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ABSTRACT 
The extent to which genetic risk factors are shared between childhood-onset (COA) and adult-onset 
(AOA) asthma has not been estimated. Based on data from the UK Biobank study (n=447,628), we 
found that the variance in disease liability explained by common variants is higher for COA (onset 
between 0-19; h2g=25.6%) than for AOA (onset between 20-60; h
2
g=10.6%). The genetic correlation 
(rg) between COA and AOA was 0.67. Variation in age-of-onset amongst COA cases had a low 
heritability (h2g=5%), which we confirmed in independent studies and also amongst AOA cases. To 
identify subtype-specific genetic associations, we performed a GWAS in the UK Biobank separately 
for COA (13,962 cases) and AOA (26,582 cases), using a common set of 300,671 controls. We 
identified 123 independent associations for COA and 56 for AOA (37 overlapped), of which 98 and 
34 were reproducible in an independent study (n=262,767). Collectively, 28 associations were not 
previously reported. For 96 COA-associated variants, the risk allele was more common in COA 
than AOA cases, including five that represent COA-specific risk factors. Conversely, we identified 
three variants that are stronger risk factors for AOA. Variants associated with obesity and smoking 
had a stronger contribution to the risk of AOA than of COA. Lastly, we identified 109 likely target 
genes of the associated variants, based primarily on correlated expression quantitative trait loci (up 
to n=31,684). GWAS informed by age-of-onset can identify subtype-specific risk variants, which 
can help understand differences in pathophysiology between COA and AOA, and so be informative 
for drug development. 
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INTRODUCTION 
The age at which asthma (MIM: 600807) symptoms first develop is often used to identify different 
disease subtypes 1-7, broadly separating patients into two groups: those with childhood- and adult-
onset disease. Perinatal factors, atopy (MIM: 147050), viral respiratory tract infections and the 
microbiome are thought to play a key role in the development of childhood-onset asthma (COA) 8-
11, whereas adult-onset asthma (AOA) is more strongly associated with obesity (MIM: 601665), 
smoking and other environmental and occupational exposures 12; 13. Such differences in aetiology 
suggest that genetic risk factors might also be partly distinct between COA and AOA. This 
hypothesis, which to our knowledge has not been formally tested to date, is supported by the 
observations that asthma risk alleles are enriched amongst cases with early onset disease 14-16. 
Moreover, it has been shown that the efficacy of novel anti-cytokine asthma therapies, such as anti-
IL-5 17 and the anti-IL-5R 18, is greater in adult-onset disease, again pointing to age-of-onset-
dependent disease mechanisms. 
 In this study, we used genetic data and information on asthma reported by participants from 
the UK Biobank study to address three main questions: to what extent do the same genetic variants 
influence the risk of both COA and AOA? Do genetic variants influence the specific age at which 
asthma first develops during childhood and during adulthood? Can we identify genetic variants that 
are risk factors for one disease subtype but not (or less so) the other? Addressing these questions 
can potentially help understand differences in pathophysiology between patients with COA and 
AOA, which may have implications for identifying age-of-onset-specific drug targets. 
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METHODS 
Selection of asthma cases from the UK Biobank study  
We first identified 53,031 individuals with self-reported doctor-diagnosed asthma amongst 488,365 
participants from the UK Biobank study 19, based on information from three data fields: 6152 (“Has 
a doctor ever told you that you have had any of the following conditions?”; touchscreen 
questionnaire), 20002 (verbal interview), 41202 (Diagnoses – main ICD10), 41204 (Diagnoses – 
secondary ICD10). Specifically, cases had: (i) a report of “Asthma” in field 6152 and a code for 
asthma in field 20002, or an ICD10 code for asthma in fields 41202 or 41204; and (ii) no report of 
COPD (MIM: 606963) in fields 6152 or 20002, nor of other respiratory diseases in field 20002. We 
then excluded 9,984 individuals (leaving 43,047) based on two data fields that recorded information 
on asthma age-of-onset: 3786 (“What was your age when the asthma was first diagnosed”, 
touchscreen questionnaire) and 22147 (“Age you were first diagnosed by a doctor”; online follow-
up questionnaire, completed only by a subset of participants). Specifically, we excluded asthma 
cases with (i) missing information for field 3786 (n=7,393); (ii) a diagnosis of asthma after the age 
of 60 (to further minimize potential confounding with COPD; n=1,723); or (iii) asthma age-of-onset 
reported in field 22147 that was >10 years apart from that reported in field 3786 (n=868). Lastly, we 
excluded 2,503 asthmatics who: (i) did not cluster within 5 standard deviations of the mean for the 
first and second MDS components estimated for individuals from the five European ancestry groups 
(CEU, GBR, FIN, IBS and TSI) of the 1000 Genomes project, as described previously 15; (ii) had 
self-reported sex different from genetically-inferred sex; (iii) were outliers when considering 
genotype missing rates and/or genome-wide heterozygosity levels; (iv) had more than 10 third 
degree relatives or were excluded from kinship inference; and/or (v) were not present in the 
imputed dataset released in July 2017. After these exclusions, there were 40,544 asthmatics 
available for analysis. 
  
Classification of UK Biobank asthma cases into three groups based on age at first diagnosis 
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We used the age at first diagnosis reported in fields 3786 and 22147 (average when both available; 
Figure S1) to group the 40,544 asthmatics into three non-overlapping groups, those first diagnosed 
as a (i) child or teenager, specifically at or before age 19 (n=13,962); (ii) young/mid adult, between 
the ages of 20 and 39 (n=11,709); or (iii) older adult, between the ages of 40 and 60 (n=14,873). We 
used a cut-off of age 19 to define childhood-onset asthma so that those diagnosed as an 
adolescent/teenager (ages 13 to 19; n=3,164) were included in the same group as those diagnosed as 
a child (ages 0 to 12; n=10,798). For heritability and genetic correlation analyses, we initially split 
those diagnosed as adults into two groups because data from longitudinal epidemiological studies 
show that asthma that is present in early to mid-adult life often has its onset in childhood 20-23. As 
such, those diagnosed between 20 and 39 were expected to represent a more heterogeneous group of 
asthma cases with respect to the underlying disease course. We used a cut-off of age 39 so that both 
groups spanned a similar age range (~20 years). We refer to the three case groups as those with 
childhood-onset asthma (COA), young adult-onset asthma (yAOA) and older adult-onset asthma 
(oAOA), respectively. Demographics for the three groups are summarized in Table S1. The main 
clinical differences between these groups were a male predominance in COA, with a female 
predominance of AOA; cases with AOA were also more likey to be obese. Based on results from the 
heritability and genetic correlation analyses, we then combined the yAOA and oAOA into a single 
AOA group (n=26,582) for genome-wide association analyses.  
 
Variation in asthma liability that is explained by genetic risk factors 
We used the BOLT-REML algorithm to estimate the proportion of phenotypic variance in asthma 
case-control status that was explained by common single nucleotide polymorphisms (SNPs), which 
we call SNP heritability (h2g). This analysis was performed separately for COA, yAOA, oAOA and 
AOA; controls for these analyses were all other individuals of European ancestry from the UK 
Biobank study who did not satisfy the specific case definition for each group and passed the quality 
controls filters described above. Specifically, we identified 433,306 individuals without COA, 
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435,559 without yAOA, 432,395 without oAOA and 420,686 without AOA. We did not exclude 
from the control groups individuals who suffered from the other asthma subtypes because this 
would have resulted in inflated heritability estimates (as a result of excluding controls who suffered 
from a genetically-correlated trait). 
We included as model SNPs in the BOLT-REML analysis ~1 million autosomal SNPs from 
HapMap3 with minor allele frequency (MAF) >1% and <2% missing rate; discrete (i.e. hard-call) 
genotypes for these SNPs were derived from the ukb_imp_chr[1:22]_v3.bgen files using PLINK 
v2.00 24, with genotype probabilities >0.1 assigned a missing genotype. We included sex and an 
indicator of the array used for genotyping as covariates. The estimated SNP heritability (and its 
standard error) was converted to the liability scale using the formula described by Lee et al. 25.  
 
Overlap in genetic risk factors between COA and AOA 
To determine the extent to which the same genetic risk factors contribute to the risk of childhood- 
and adult-onset asthma, we used BOLT-REML as described above to estimate the pairwise genetic 
correlation between COA (13,962 cases and 433,306 controls) and: (i) yAOA (11,709 cases and 
435,559 controls); (ii) oAOA (14,873 cases and 432,395 controls); and (iii) AOA (26,582 cases and 
420,686 controls). Pairs of genetic correlations were compared statistically using a Z-test. For 
comparison, genetic correlations were also estimated with a different approach, LD-score 
regression26, based on association results from ~1 million autosomal SNPs from HapMap3.  
To understand if the genetic aetiology of COA and AOA had a comparable allergic 
component, we used BOLT-REML to estimate the genetic correlation between asthma onset 
subtypes and a hay fever (MIM: 607154) / eczema (MIM: 603165) combined phenotype created 
using information provided in data field 6152, which asked “Has a doctor ever told you that you had 
any of the following conditions?”. When considering individuals of European descent who 
answered this question and did not meet the exclusion filters described above, 106,782 selected the 
“Hayfever, allergic rhinitis or eczema” option and so were considered to be cases, while the 
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remaining 353,418 individuals were considered to be controls.  
 
Contribution of common SNPs to variation in age at first diagnosis  
The SNP heritability of age at first diagnosis in the UK Biobank study was estimated separately for 
COA (n=13,962) and AOA (n=26,582) cases using BOLT-REML as described above. Age at first 
diagnosis was quantile-normalized (with ties broken randomly) prior to the BOLT-REML analysis. 
We also determined if the observed heritability of age-of-onset in UK Biobank COA cases was 
consistent with that estimated when considering data from 4,718 cases with COA identified in two 
independent studies described below: the Avon Longitudinal Study of Parents and Children 
(ALSPAC)27, described in detail in the Supplemental Methods, and the Child and Adolescent Twin 
Study in Sweden (CATSS). 
ALSPAC27. We identified 1,326 unrelated children of European descent with a positive 
response to the question “Did your child have asthma in the past 12 months?” included in surveys 
completed when the child was approximately 7, 8, 9, 11 or 13 years old. Age-of-onset was defined 
as the age at which “wheeze” or “wheezing and whistling” was first reported in these surveys. The 
presence of wheeze was identified based on a positive response to the question: “Has your child had 
wheezing, breathlessness or episodes of stopping breathing in past 12 months or since he was (age 
at last Q)?”. “Wheezing and whistling” was identified based on a positive response to the question: 
“Has your child had any periods when there was wheezing with whistling on his chest when he 
breathed in past 12 months or since he was (age at last Q)?”. We then performed a GWAS of age-of-
onset (quantile-normalized) using SNPTEST with sex included as a covariate; we tested 8.4 million 
SNPs imputed based on the 1000 Genomes Project reference panel (phase 1, version 3, release Dec 
2013). 
 Child and Adolescent Twin Study in Sweden (CATSS)28. Data on asthma during childhood 
was collected from parental questionnaires conducted through the Swedish Twin Register for twins 
born between 1992-1999, completed when the twins were aged 9 and 15. Specifically, the parents 
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reported the age at which the twins first had asthma/wheezing or breathlessness. This information 
was supplemented with data from: (i) the National Patient Register (NPR)29, specifically the age at 
which asthma was first diagnosed by a doctor, based on ICD-10 code J45 or J46, or ICD-9 code 
493; and (ii) the Swedish Prescribed Drug Register (SPDG), specifically the age at which the first 
asthma preventer medication was recorded (ATC codes R03AK, R03BA, R03DC), for anyone with 
two or more prescriptions before age 20. Asthma age-of-onset was defined as the youngest age 
across all three data sources (i.e. parental questionnaires, NPR and SPDG). After excluding 
individuals of non-European ancestry, we identified 3,392 twins with asthma onset at or before age 
19. DNA samples from these twins were genotyped on the Illumina PsychChip (which includes a 
GWAS backbone, consisting of 265,000 tag SNPs) and, following sample and SNP quality control 
(described in the Supplemental Methods), imputed to the 1000 genomes phase 3 reference panel. 
The association between age-of-onset (quantile-normalized) and SNP allelic dosage was tested with 
RAREMETALWORKER version 4.13.8, accounting for known relatedness within the sample. 
Meta-analysis and estimation of SNP heritability. Age-of-onset GWAS results from the 
ALSPAC and CATSS studies were combined using an inverse-variance-weighted, fixed-effects 
meta-analysis, using METAL 30. We then applied the LD-score regression approach 31 to the meta-
analysis results to estimate the proportion of variance in age-of-onset explained by common 
variants, based on 1.1 million HapMap3 SNPs. 
 
Identification of genetic associations with COA and AOA 
We performed a GWAS of COA (13,962 cases vs. 300,671 controls) and a GWAS of AOA (26,582 
cases vs. 300,671 controls) in the UK Biobank study, using a common set of 300,671 controls who 
did not suffer from any allergic disease (asthma, hay fever, eczema or other allergies). We used this 
selected subset of controls for the GWAS, and not the larger set (~430,000) used in the heritability 
analyses, because the power to detect associations with asthma can be improved by excluding from 
the control group individuals who suffer from other genetically-correlated allergic diseases 32. 
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To identify the 300,671 non-allergic controls we used information provided on the data 
fields described above (6152, 20002, 41202, 41204), as well as 22127: “Has a doctor ever told you 
that you have had any of the conditions below”, which included “Hay fever or allergic rhinitis” and 
“Asthma” as possible answers. SNPs were tested for association using the linear mixed model 
implemented in BOLT-LMM 33, which accounted for the presence of related individuals and any 
residual population stratification amongst Europeans. We included as model SNPs 553,880 
autosomal variants that were directly genotyped, had an MAF>1%, call rate >95% and Hardy 
Weinberg equilibrium P-value >10-6. Age, sex and an indicator of the genotyping array used were 
included as discrete covariates.  
 Of the 92 million variants with imputed data released by the UK Biobank, we retained 
results for 9 million variants that had (i) a MAF >1%; (ii) matching alleles and were polymorphic in 
Europeans (n=294) of the 1000 Genomes project; (iii) a unique reference sequence (rs) number and 
genomic position (based on hg19); and (iv) an imputation info score >0.5. For each SNP, the beta 
and SE was estimated based on a linear model, and so it was subsequently adjusted using the 
formulae adj_beta = beta/(mu*(1-mu)) and adj_SE = SE/(mu*(1-mu)), where mu is approximated 
by the case/control ratio. The resulting SE was then inflated by the square root of the LD-score 
regression34 intercept (respectively 1.039 and 1.018 for COA and AOA), which likely reflects 
inflation of test statistics due to unaccounted biases, and the association P-value re-calculated using 
the corrected SE. We used a P-value threshold of 3x10-8 for genome-wide significance, as suggested 
for studies that analyse variants with a MAF >1% 35. 
 As secondary analyses, the same approach was used to perform a GWAS of (i) asthma onset 
type, specifically comparing COA cases (n=13,962, coded as “1”) against AOA cases (n=14,873, 
coded as “0”), i.e. a case-only association analysis; and (ii) asthma case-control status, with cases 
identified irrespective of age at first diagnosis (40,544 cases vs. 300,671 controls; SE and P-value 
adjusted for an LD-score regression intercept of 1.053). The latter analysis was performed to 
determine how many associations identified in the COA or AOA GWAS would have been identified 
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had we instead performed a GWAS of asthma that was not informed by age-of-onset information. 
 
Identification of variants with a statistically independent association with asthma risk 
We used the approximate joint association analysis option of GCTA 36 to identify variants that 
remained associated with asthma risk at a P<3x10-8 in the COA and AOA GWAS after accounting 
for the effects of nearby (<10 Mb) more strongly associated variants. We refer to these as sentinel 
risk variants. LD was estimated based on a random subset of 5,000 individuals from the UK 
Biobank study. 
 
Validation of SNP associations  
To determine if SNP associations identified in the UK Biobank study were reproducible, we used 
the same age cut-offs described above to identify COA cases, AOA cases and allergy-free controls 
(i.e. no asthma, eczema, rhinitis or any other allergic conditions) amongst research participants of 
the personal genetics company 23andMe, Inc (Supplementary Methods). After restricting the 
analyses to unrelated individuals of confirmed European descent, sample sizes for the three 
association analyses performed in the replication study were as follows: (i) 31,759 COA cases vs. 
214,890 controls; (ii) 16,297 AOA cases vs. 217,711 controls; and (iii) 31,002 COA cases (coded 
‘1’) vs. 16,297 AOA cases (coded ‘0’). The number of controls was lower in analysis (i) than (ii) 
because an additional 2,821 controls were relatives of COA cases, and so were excluded from the 
analysis. Similarly, 757 COA cases were relatives of AOA cases, and so were no included in 
analysis (iii). Sentinel SNPs identified in the UK Biobank GWAS were tested for association in the 
23andMe study using logistic regression, assuming an additive model for allelic effects and 
including as covariates age, sex and five ancestry-informative principal components. Association 
results from these analyses were conservatively adjusted for a genomic control inflation factor of 
1.101, 1.061 and 1.047, respectively.  
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Sentinel risk variants not previously implicated in the aetiology of allergic disease 
To determine if a sentinel variant was in LD with a SNP previously reported to associate with any 
allergic disease, we (i) identified all SNPs in LD (r2>0.05) with that sentinel variant, using genotype 
data from individuals of European descent from the 1000 Genomes Project 37 (n=294, release 
20130502_v5a); and (ii) determined if the sentinel variant or any of the correlated SNPs identified 
were reported to associate with any allergic disease (asthma, hay fever, eczema, food allergy or 
atopy) in the NHGRI-EBI GWAS catalog database 38, which was downloaded on the 30th of 
September 2018. 
 
Genetic correlation between COA and AOA and other complex diseases/traits  
To provide some insight into potential differences in genetic aetiology between COA and AOA, we 
used the LD-score regression approach to estimate the pairwise genetic correlation between each 
disease subtype and 227 common traits or diseases with GWAS data currently available in LD Hub 
39. We uploaded to LD Hub association results from ~1.1 million HapMap3 SNPs, obtained when 
comparing 13,962 cases vs. 433,306 controls for COA, and 26,582 cases vs. 420,686 controls for 
AOA, as done in the BOLT-REML analysis. 
 
Predicting target genes of sentinel variants based on LD with eQTL and non-synonymous 
SNPs 
We performed the following steps to identify genes for which variation in gene expression and/or 
protein sequence was associated with sentinel SNPs identified in the COA and AOA GWAS.  
First, we identified SNPs associated with variation in gene expression (i.e. expression 
quantitative trait loci, eQTL) in published transcriptome studies of five broad tissue types relevant 
for asthma: individual immune cell types, lung, skin, spleen and whole-blood. We identified a total 
of 50 transcriptome studies reporting results from eQTL analyses in any one of those five tissue 
types (Table S2). Some studies included multiple cell types, experimental conditions and/or eQTL 
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types, resulting in a total of 130 separate eQTL datasets. For each eQTL dataset, we then (i) 
downloaded the original publication tables/files containing results for the eQTL reported; (ii) 
extracted the SNP identifier, gene name, association P-value and directional effect (if available; 
beta/z-score and effect allele); (iii) excluded eQTL located >1 Mb of the respective gene (i.e. trans 
eQTL), because often these are thought to be mediated by cis effects 40; (iv) excluded eQTL with an 
association P>8.9x10-10, a conservative threshold that corrects for 55,765 genes (based on 
GENCODE v19), each tested for association with 1,000 SNPs (as suggested by others 41-43); and (v) 
for each gene, used the --clump procedure in PLINK 24 to reduce the list of eQTL identified (which 
often included many correlated SNPs) to a set of ‘sentinel eQTL’, defined as the SNPs with 
strongest association with gene expression and in low LD (r2<0.05, linkage disequilibrium (LD) 
window of 2 Mb) with each other. 
Second, we identified genes for which a sentinel eQTL reported in any of the 130 eQTL 
datasets described above was in high LD (r2>0.8) with a sentinel variant identified in the COA or 
AOA GWAS. That is, we only considered genes for which there was high LD between a sentinel 
eQTL and a sentinel asthma risk variant, which reduces the chance of spurious co-localization.  
Third, we used wANNOVAR 44 to identify genes containing non-synonymous SNPs 
amongst all variants in LD (r2>0.8) with any sentinel variants. SNPs in LD with sentinel variants 
were identified using genotype data from individuals of European descent from the 1000 Genomes 
Project 37 (n=294, release 20130502_v5a).  
  
Ethical approval for the study was obtained from the Human Ethics Committee of the QIMR 
Berghofer Medical Research Institute; and the ALSPAC Ethics and Law Committee and the Local 
Research Ethics Committees. 
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RESULTS 
 
Overlap in genetic risk factors between childhood- and adult-onset asthma 
When cases in the UK Biobank study were defined as asthmatics who reported disease onset as a 
child (age 0 to 19, n=13,962; demographics in Table S1) and controls as all other individuals 
(n=433,306), the liability scale SNP heritability (h2g) estimated with the BOLT-REML algorithm
45 
was 25.6% (SE=0.67%; Table 1). Substantially lower SNP heritability estimates were obtained 
when considering asthmatics who reported developing asthma as a young (age 20 to 39; 11,709 
cases vs. 435,559 controls) or older (age 40 to 60; 14,873 cases vs. 432,395 controls) adult: 
h2g=9.8% (SE=0.59%) and h
2
g=7.8% (SE=0.49%), respectively (Table 1).  
We then estimated the extent to which the same genetic risk factors contributed to the 
heritability of childhood- and adult-onset asthma. Using BOLT-REML, we observed a modest 
genetic correlation (rg=0.47, SE=0.03; Table 1) between childhood-onset asthma (COA) and older 
adult-onset asthma (oAOA). Similar results were obtained with the LD-score regression approach 
(rg=0.42, SE=0.06). In contrast, larger genetic correlations were observed between young adult-
onset asthma (yAOA) and both COA (rg=0.83, SE=0.03)
 and oAOA (rg=0.86, SE=0.05).  
 The large genetic correlation observed between yAOA and oAOA, together with their 
similar heritability estimates, suggests that most SNPs associated with disease risk in adult-onset 
asthma have broadly similar allele frequencies in yAOA and oAOA cases. This is not the case 
between COA and yAOA, nor between COA and oAOA, given the large differences in SNP 
heritability and, in the case of oAOA, also the modest pairwise genetic correlation. For these 
reasons, we then combined the yAOA and oAOA cases into a single group with AOA (n=26,582). 
When we compared AOA cases against all other individuals as controls (n=420,686), we observed a 
SNP heritability on the liability scale of 10.6% (SE=0.38%), with a genetic correlation with COA 
estimated to be 0.67 (SE=0.023; Table 1). Similar results were obtained with LD-score regression 
(rg=0.63, SE=0.054). These results show that the genetic correlation between COA and AOA is 
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significantly lower than 1 (P=10-46). 
To investigate if the genetic aetiology of COA had a larger allergic component than AOA, 
we then estimated their pairwise genetic correlation with a combined hay fever/eczema phenotype 
measured in the same UK Biobank participants (n=447,268). Using BOLT-REML, we found that 
genetic risk factors for hay fever/eczema (h2g=15.6%, SE=0.26%) significantly overlapped those for 
both COA and AOA, but the overlap was larger for the former: rg=0.70 (SE=0.013) vs. rg=0.57 
(SE=0.017). Similar results were obtained when considering doctor-diagnosed hay fever (rg=0.67 
vs. rg=0.56), which was available for a subset of UK Biobank individuals (n=111,664).  
Collectively, these results demonstrate that in the UK Biobank study, asthma reported to first 
develop as a child has a genetic architecture that is partly similar and partly distinct from asthma 
reported to first develop as an adult.  
 
Contribution of common SNPs to variation in age at first diagnosis amongst cases with COA 
and AOA 
Next, we used BOLT-REML to test if common SNPs also influenced the specific age at which 
asthma was diagnosed during childhood and, separately, during adulthood. We first performed this 
analysis in the 13,962 cases with COA in the UK Biobank study. We found that only 5.1% 
(SE=2.2%) of the variance in self-reported asthma age-of-onset was explained by common SNPs, 
an estimate that was borderline significantly greater than 0% (P=0.011). Similar results were 
obtained using the GCTA-GREML approach (4.5%, SE=2.2%, P=0.017). To confirm this finding, 
we then performed the same analysis in two independent studies conducted in children: ALSPAC 
(n=1,326) and CATSS (n=3,392), for a combined sample size of 4,718 cases with COA. We 
obtained a similarly low estimate of SNP heritability (3.0%, SE=9.3%) in this combined dataset 
using the LD-score regression approach 26. Similar results were also obtained when considering the 
26,582 individuals from the UK Biobank study with AOA (onset between 20 and 60): h2g=4.4% 
(SE=1.2%). These findings indicate that common SNPs explain only a small amount of variation in 
 16 
 
self-reported age-of-onset amongst COA and AOA cases. 
 
Identification and validation of genetic associations with COA and AOA 
We then set out to identify genetic risk factors for COA and AOA separately. In a GWAS of 
COA (Figure 1 and Figure S2), which included 13,962 cases and 300,671 controls from the UK 
Biobank study who did not report any allergic disease (i.e. individuals without asthma, hay fever, 
eczema or other allergies), we identified 123 SNPs with an independent association with disease 
risk at a P<3x10-8 (which we call sentinel SNPs; Table S3), located in 83 loci >1Mb apart. In a 
separate GWAS of AOA (26,582 cases and the same 300,671 controls; Figure 1 and Figure S3), we 
identified 56 sentinel risk SNPs (in 40 loci), including 19 that were in low LD (r2<0.05) with COA 
sentinel variants (Table S4). Consistent associations for all sentinel variants were observed when 
individuals with hay fever, eczema or other allergies were not excluded from the control group 
(Figure S4). 
Overall, 27/123 (22%) COA and 5/56 (9%) AOA associations would not have been 
identified at the genome-wide significance level had we compared all asthma cases (i.e. irrespective 
of age-of-onset, n=40,544) against the same 300,671 controls (Tables S5 and S6). For example, the 
COA variant rs9391997 (in IRF4 [MIM:601900]) had only a modest association with asthma risk 
when considering all asthma cases (OR=1.02, P=0.001).  
To replicate the associations identified, we used data from research participants of the 
personal genetics company 23andMe, Inc. Using the same age cut-offs as for the UK Biobank 
study, and after restricting the analyses to unrelated individuals of confirmed European descent, 
there were 31,759 COA cases and 214,890 asthma- and allergy-free controls. Of the 123 sentinel 
SNPs identified in the UK Biobank GWAS of COA, 108 were available for replication, of which 98 
had both a (1) reproducible association (P<0.05 and same direction of effect) in the independent 
23andMe study per se; and (2) a genome-wide significant association in the meta-analysis of the 
UK Biobank and 23andMe studies (45,721 COA cases vs. 515,561 controls; Table 1 and Table S7).  
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For AOA, data were available for 16,297 cases and 217,711 controls in the 23andMe study. 
Using the same criteria, 34 (of 46 tested) sentinel SNPs for AOA were associated with disease risk 
in the 23andMe study and in the overall meta-analysis (42,879 cases vs. 518,382 controls; Table 2 
and Table S8).  
  
Shared or disease onset-specific SNP associations?  
To formally test if the 132 (98+34) SNP associations identified differed between COA and AOA, for 
each sentinel variant we compared the frequency of the risk allele between COA and AOA cases. 
Based on combined results from the UK Biobank and 23andMe studies (44,964 COA cases vs. 
42,879 AOA cases), we found that the risk allele was more common in COA than AOA cases for all 
98 COA sentinel variants, significantly so for 96 SNPs (P<0.05; Table S9). Therefore, most if not 
all 98 COA sentinel SNPs are stronger risk factors for COA than for AOA. At least five sentinel 
SNPs are likely to represent COA-specific risk factors (Figure 2A), because they were not 
associated with AOA risk (OR~1 in the meta-analysis of UK Biobank and 23andMe studies; Table 
S9). 
A similar pattern of results was observed for 31 of the 34 sentinel SNPs identified for AOA 
(Table S10), that is, the risk allele was observed at a significantly higher (22 SNPs) or similar (nine 
SNPs) frequency in COA than AOA cases. For the remaining three AOA sentinel SNPs (rs2381712 
near TEX41, rs2544026 in HDAC7 [MIM: 606542] and rs28635831 in COG6 [MIM: 606977]), we 
observed a different pattern of results: the risk allele was significantly more common in AOA than 
COA cases, suggesting that they are stronger risk factors for AOA. Notably, one of these SNPs is 
likely to represent an AOA-specific risk factor, given the lack of association with COA (OR~1): 
rs2381712 near TEX41 (Figure 2B and Table S10).  
Of the seven SNPs reported in two GWAS of asthma age-of-onset published previously 
{Sarnowski, 2016; Forno, 2012} – located in/near IL1RL1, HLA-DQA1, IL33, CYLD, GSDMB, 
CRBN and ETS1 – six were tested in our analysis, with four having a consistent association (Table 
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S11). The two variants for which the reported association was not supported by results from our 
analysis were located in/near CYLD and CRBN; both were not associated with asthma onset type 
(Table S11), nor COA or AOA risk (not shown). 
 
Sentinel variants not reported in previous GWAS of asthma or other allergic diseases 
We determined which of the 132 sentinel variants identified above represented novel associations 
for allergic disease in general, that is, when considering all previously reported associations with 
P<5x10-8 for asthma, hay fever, eczema, food allergy and/or atopy. Of the 98 sentinel variants 
confirmed for COA, 73 were in LD (r2>0.05) with variants previously reported to associate with 
allergic disease (Table S12), while the remaining 25 represent novel SNP associations at the 
genome-wide significance level (Table 1). Of the 34 sentinel associations for AOA, 28 have 
previously been described (Table S13), but six were novel (Table 2), including three not discovered 
in our GWAS of COA (in/near PTPRC [MIM: 151460], TEX41 and COG6). Therefore, overall we 
identified 28 (25+3) novel associations for asthma. 
 
Genetic correlation between COA and AOA and other complex diseases/traits  
To provide some clues into the potential differences in genetic aetiology between COA and AOA, 
we estimated the overlap in genetic risk factors between COA and AOA and 227 human traits or 
diseases with publicly available GWAS results, using LD Hub 39. We observed a number of genetic 
correlations that were significantly different from 0 (at a P<0.05/227=0.0002; Table S14), of which 
we highlight three groups. First, significant correlations with a similar magnitude between COA and 
AOA were observed for lung function traits, for example FEV1/FVC (rg=-0.35 for both). Because 
the SNP heritability of COA was larger than that of AOA, these results indicate that genetic variants 
that influence variation in lung function explain a larger proportion of variation in disease risk for 
COA than for AOA. Second, the genetic correlation was significant with COA but not with AOA for 
two traits: eczema (rg=0.60 vs. rg=0.04) and years of schooling (rg=0.11 vs. rg=-0.09). Lastly, the 
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genetic correlation was significant with AOA but not with COA for six sets of traits: (i) obesity-
related traits (e.g. being overweight, rg=0.08 vs. rg=0.28); (ii) age when first child was born 
(rg=0.07 vs. rg=-0.27); (iii) ever smoker (rg=-0.07 vs. rg=0.23); (iv) rheumatoid arthritis (rg=-0.09 
vs. rg=0.18; [MIM: 180300]); (v) insomnia (rg=-0.03 vs. rg=0.21); and (vi) depressive symptoms 
(rg=0.02 vs. rg=0.19).  
 
Likely target genes of the sentinel risk variants 
Finally, we found that 11 sentinel variants were in high LD (r2≥0.8) with missense or non-
synonymous SNPs in 12 genes, including four with variants that were predicted to have a damaging 
effect on the protein by both SIFT and PolyPhen-2: HLA-C, ITGB8, NOD2 and TESPA1 (Table 
S15). On the other hand, 62 sentinel variants were in high LD with a sentinel eQTL associated with 
gene expression in disease-relevant tissues or cell types at a conservative P<8.9x10-10 (Table S2), 
implicating an additional 97 genes as likely targets of asthma risk variants (Tables S16 and S17). 
Of the 109 genes (12+97; Table S18), 25 were the predicted targets of novel sentinel risk SNPs for 
asthma (Table 3), of which we highlight seven based on a stricter LD threshold (r2>0.95): CCL20 
(rs10187276; [MIM: 601960]); IL2RA (rs12722502; [MIM: 147730]); PRKCQ (rs943451; [MIM: 
600448]); PRR5L (rs10836538; [MIM: 611728]); CCR12P (rs4771332); TESPA1 (rs62623446; 
[MIM: 615664]); NSMCE1 (rs3785356; [MIM: 617263); NOD2 (rs2066844; [MIM: 605956]); 
RP11-729L2.2 and SMAD4 (rs1893380; [MIM: 600993]); and GPX4 (rs892225; [MIM: 138322). 
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DISCUSSION 
We found that in the UK Biobank study (i) common genetic variants collectively explain a larger 
fraction of variation in liability to COA than AOA; (ii) the genetic correlation between COA and 
AOA is high but significantly different from 1; and (iii) variation in the specific age at which 
asthma first develops within each asthma subtype has a low SNP heritability. We also identified and 
validated 98 independent genetic associations for COA and 34 for AOA, and 109 likely target genes 
of the risk variants. 
 The observed difference in SNP heritabilities between COA and AOA, together with a 
genetic correlation that was significantly different from 1, indicates that the genetic architectures of 
COA and AOA are similar but not identical. Exactly how they might differ is unclear, as the 
observed heritabilities and genetic correlation might arise under difference scenarios. For example, 
a genetic correlation different from 1 might arise not only when there are subtype-specific risk 
variants (i.e. associated with one disease subtype but not the other) but, in some situations, even 
when all risk variants are shared between COA and AOA, as shown by Carey et al. 46. Specifically, 
a genetic correlation will be lower than 1 even when all risk loci are shared if there is little (or no) 
correlation in genetic effects between the two diseases. The latter scenario is relatively extreme, and 
is not supported from results of our GWAS, which found evidence for subtype-specific associations. 
A more realistic scenario is that for some variants, genetic effects are highly correlated between 
COA and AOA, and so these contribute to a higher genetic correlation. In contrast, other variants 
might have subtype-specific associations, or genetic effects that are weakly correlated between 
COA and AOA; such variants would contribute to a lower genetic correlation. Under such model, 
where the correlation in genetic effects differs between groups of variants, on balance the genetic 
correlation between COA and AOA would be high but significantly different from 1. Association 
results for the sentinel SNPs identified in our GWAS suggest that this model is plausible (Figure 2). 
The observation that COA and AOA have partly distinct genetic architectures is perhaps 
surprising given their broad similarity in clinical presentation. For comparison, COA had a similar 
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genetic overlap with a combined hay fever/eczema phenotype (rg=0.7) as it did with AOA. We 
speculate that these results imply that there may be distinct genes or molecular pathways involved 
in COA but not (or less so) in AOA, or vice-versa, in which case identifying such pathways could 
inform the development of drugs tailored specifically for COA or AOA. Another possibility, 
however, is that a particular gene contributes to the pathophysiology of both disease subtypes, with 
its expression being dysregulated in COA and AOA cases by different mechanisms: inherited risk 
alleles in the former and acquired epigenetic modifications in the latter. Such epigenetic 
modifications in AOA cases could potentially result from long-term exposure to environmental risk 
factors, such as a low-quality diet 47 or smoking 48. For example, we recently highlighted that lower 
expression of PITPNM2 (MIM: 608920), a gene potentially involved in neutrophil function, is 
independently associated with an allergy-predisposing allele and smoking-induced CpG 
methylation 15. Studies that carefully investigate the contribution of epigenetic modifications to the 
aetiology of asthma, particularly with adult onset, are warranted; we suggest to first investigate 
genes implicated by genetic studies. 
 Results from our heritability analysis also indicate that common SNPs explain only about 
5% of the variation in the specific age at which asthma was reported to be diagnosed during 
childhood and during adulthood. This observation, together with the widespread allele frequency 
differences observed between COA and AOA cases, indicates that SNP associations discovered 
when analyzing the full spectrum of age-of-onset (i.e. spanning early childhood to older adulthood) 
must be interpreted with care. Specifically, it should be considered if a specific association is likely 
to reflect allele frequency differences between cases with different asthma onset subtypes (e.g. COA 
vs. AOA), or between cases with the same asthma subtype (e.g. COA) but with different age-of-
onset. Our results suggest that the former scenario will be more common than the latter. By 
extension, our findings also suggest that measurement error and/or environmental risk factors have 
the largest contribution to variation in specific age-of-onset within each disease subtype. In 
childhood, candidate environmental risk factors that might affect age-of-onset include the timing, 
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frequency and duration of chest infections, allergen exposure, pet ownership, maternal smoking and 
low-quality diet during pregnancy 49-55. In adulthood, additional risk factors might include 
occupational exposures, active smoking and obesity 20; 22; 56-58.  
 To identify genetic risk factors that could be specific to COA or AOA, we performed two 
GWAS in the UK Biobank study, separately comparing 13,962 COA cases and 26,582 AOA cases 
against a common set of 300,671 asthma and allergy-free controls. Despite a relatively small case 
sample size in the GWAS of COA, we identified a large number of independent SNP associations 
with asthma risk, 123 in total. A relatively smaller number of associations (56) were identified in the 
GWAS of AOA, consistent with the lower overall SNP heritability estimated for this disease 
subtype. For comparison, the largest number of independent associations reported to date in a single 
GWAS of asthma was 27 (based on 28,399 cases and 128,843 controls 59).  
To validate the observed associations, we repeated the association analyses in the 
independent 23andMe study, comprising a total of 265,767 individuals. Of the 179 (123+56) 
associations discovered in the UK Biobank study, 132 (98+34) were also detected in the replication 
study, and remained genome-wide significant in the combined analysis. Taking into account all 
associations reported to date for allergy-related traits in the GWAS catalog 60, and based on a 
conservative LD r2 threshold of 0.05, 28 of the combined 132 sentinel risk SNPs were found to 
represent novel associations for asthma. Amongst these were the first two genome-wide significant 
associations for asthma reported for variants on the X-chromosome: rs850637, which overlaps a 
predicted transcription factor binding site for RELA and is located between TLR7 (MIM: 300365) 
and TLR8 (MIM: 300366), two genes involved in anti-viral immunity61-63; and rs5953283 located 
18 kb upstream of FOXP3 (MIM: 300292), which is central to the establishment and maintenance 
of regulatory T cells 64.  
 To determine if the associations with COA and AOA were likely to be subtype-specific, we 
then compared the frequency of the disease-predisposing allele for each sentinel risk SNP between 
the COA and AOA cases. We found that for most sentinel SNPs, identified in either the COA or 
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AOA GWAS, the predisposing allele was significantly more common in COA than AOA cases, 
consistent with a stronger association with COA. This includes five variants that are likely to 
represent COA-specific risk factors, because the frequency of the predisposing allele was similar in 
AOA cases compared to non-asthmatic controls (i.e. OR~1 in the GWAS of AOA). Based on LD 
with sentinel eQTLs and non-synonymous variants, we were able to identify a likely target gene for 
only one of these five COA-specific risk variants (rs4574025): PIGN (MIM: 606097), a component 
of the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway 65, which is involved in 
anchoring proteins to the cell surface 66 and in ATP release 67. 
 We also found one example of a sentinel SNP that is likely to represent an AOA-specific risk 
factor: rs2381712 near TEX41, which encodes a long non-coding RNA. Of note, rs2381712 is in 
moderate LD (r2=0.41; D’=0.75) with a variant (rs10193706) reported to associate with smoking 
behavior (heavy vs. never smokers) 68. The rs10193706:C allele that was associated with being a 
heavy smoker was associated with a lower risk of AOA, which is unexpected given that smoking is 
thought to be a risk factor for AOA and the overall positive genetic correlation that we observed 
between smoking behavior and AOA risk. As such, it is possible that the two associations 
(rs2381712 with AOA, and rs10193706 with smoking) do not tag the same underlying causal 
variant. We did not find any sentinel eQTLs or non-synonymous SNPs in high LD with rs2381712, 
and so the likely target gene of this risk variant remains to be identified. A nearby gene of potential 
interest to asthma is ZEB2 (MIM: 605802), which encodes a transcription factor that regulates T 
cell and dendritic cell development 69-71, as well as mast cell signaling 72. 
 For two additional sentinel SNPs, the observed difference in risk allele frequency between 
the two case groups (AOA > COA) suggests that they represent stronger risk factors for AOA: 
rs2544026 in HDAC7 and rs28635831 in COG6. HDAC7 was identified as a likely target gene of 
rs2544026 based on eQTL information from macrophages exposed to live bacterial pathogens 
(Listeria and Salmonella), with results consistent between two different eQTL studies 73; 74. 
Specifically, in infected macrophages but not in non-infected cells, the rs2544026:T disease-
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predisposing allele was associated with lower HDAC7 expression. This observation is consistent 
with reduced overall HDAC activity in patients with asthma 75; 76 and COPD 77. How lower HDAC7 
expression in infected macrophages might then result in a higher risk of asthma needs to be 
determined. Because HDAC7 is thought to be a repressor of macrophage-specific genes 78, one 
possibility is that lower HDAC7 expression in macrophages results in a more exuberant 
inflammatory response against bacterial infections, which might contribute to an asthma-prone 
environment in the airways. Interestingly, COG6 was also identified as a likely target of rs28635831 
based solely on eQTLs described in macrophages stimulated with Salmonella81. Variants in 
moderate to high LD with rs28635831 have been reported to associate with auto-immune diseases, 
namely psoriasis (MIM: 177900)79, rheumatoid arthritis and lupus erythematosus (MIM: 152700)80. 
COG6 is part of the conserved oligomeric Golgi complex, with mutations in this gene described in 
patients with congenital disorders of glycosylation; core clinical features include recurrent 
infections and hyperkeratosis 81. These observations suggest that COG6 might play a role in 
immune cell function; studies that address this possibility are warranted. 
Results from the genetic correlation analysis between COA/AOA and other complex 
traits/diseases provided some clues into disease mechanisms that are dysregulated by genetic 
variants in one disease subtype but not (or less so) in the other. First, we found a larger genetic 
correlation with eczema for COA than AOA. This observation, which supported findings from the 
genetic correlation analysis with hay fever that we performed in the UK Biobank study, indicates 
that SNPs that influence molecular pathways underlying allergies explain a larger proportion of 
variation in disease risk for COA than for AOA. Second, we found that alleles associated with 
achieving a higher education level were collectively associated with a higher risk of COA, 
consistent with some epidemiological studies 82; 83, but a lower risk of AOA. These opposing effects 
suggest that different mechanisms underlie both associations. For example, on the one hand, the 
development of asthma in childhood might result in an increased preference later in life for a 
professional career that requires a higher education. On the other hand, higher education is 
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associated with a lower BMI in adulthood 84, which is protective for asthma. These potential causal 
relationships and other possible explanations (e.g. genetic pleiotropy) for the observed genetic 
correlations with education attainment should be explored in future studies. Lastly, we found that 
variants associated with three risk factors for asthma – obesity, smoking and age at first birth (or 
puberty) – had a stronger contribution to the risk of AOA than of COA. As highlighted above, a 
significant genetic correlation might arise because of a causal effect of these risk factors on asthma 
risk 85-88. At least for obesity, such causal effect does not appear to extend to other allergies 89, 
which could potentially explain the difference in genetic correlation between AOA and COA. 
A caveat of our analysis is that some asthma cases from the UK Biobank included in the 
AOA group might not have recollected a physician’s diagnosis of asthma as a child. Such 
misclassification of true COA as AOA would tend to inflate the estimate of the genetic correlation 
between COA and AOA, and also to decrease power to detect AOA-specific SNP associations. 
In conclusion, we show that childhood-onset asthma has a genetic aetiology that is partly 
distinct from asthma that first develops in adult life. GWAS informed by age-of-onset can identify 
subtype-specific genetic risk factors, which can help understand differences in pathophysiology 
between childhood and adult asthma.   
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FIGURE TITLES AND LEGENDS 
 
Figure 1. Summary of association results from the GWAS of COA and AOA in the UK 
Biobank study. The middle panel shows the Manhattan plots (left for childhood-onset asthma 
[COA], based on 13,962 cases and300,671 controls; right for adult-onset asthma [AOA], based on 
26,582 cases and 300,671 controls) with variants associated with disease risk at a P<3x10-8 (red 
vertical line) highlighted in red; associations with P<10-21 are shown with P=10-21. For COA, 
sentinel variants that were in low LD (r2<0.05) with previous reported associations for allergic 
disease are shown with a black circle (25 out of 123 in total), with the green line pointing to 
additional information on the adjacent left panel. Specifically, the left panel indicates: (1) if the 
association with COA replicated in the independent 23andMe study (P<0.05 and same direction of 
effect; “1”=yes, “0”=no, “NA”=results not available); (2) the minor allele frequency (MAF; in %) 
in the case group, with the square indicating whether the risk allele occurred at a significantly 
greater (in black; P<0.05 and OR>1 in the COA vs. AOA case-case analysis, i.e. stronger risk factor 
for COA), similar (in grey; P≥0.05 in the case-case analysis, i.e. similar association with COA and 
AOA) or lower (in white; P<0.05 and OR<1 in the case-case analysis; i.e. stronger risk factor for 
AOA) frequency in COA when compared to AOA cases; and (3) the location of the sentinel risk 
variant relative to the nearest genes (in black font) or, for variants with an association that replicated 
in the 23andMe study and with a target gene prediction, the likely target gene(s) based on LD 
(r2>0.8) with non-synonymous or sentinel eQTL (in blue font). The location of the sentinel risk 
variant (when shown) is indicated by “gene1--[]--gene2”, the two closest genes (upstream and 
downstream), when the variant was intergenic; the distance to each gene is proportional to the 
number of “-“ shown. Otherwise, when the risk variant was located within a gene, the respective 
gene name is shown between square brackets (i.e. [gene]). The right panel shows the same 
information for all 56 sentinel variants associated with AOA, which were grouped into those that (1) 
were in LD (r2>0.05) with sentinel variants identified in the COA GWAS (37 variants; highlighted 
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by a black line); (2) were in LD (r2>0.05) with previous reported associations for allergic disease (8 
variants; highlighted by an orange line); or (3) were not in LD (r2<0.05) with sentinel variants for 
COA, nor with previous reported associations for allergic disease (11 variants; highlighted by a 
green line).  
 
Figure 2. Association between sentinel variants and risk of COA and AOA. The two panels (A 
and B) respectively show results for COA and AOA sentinel SNPs identified in the UK Biobank 
GWAS and that subsequently validated in the 23andMe replication study. The x-axis shows SNP 
effects (odds ratio; “OR”) estimated in the COA vs. control meta-analysis of the UK Biobank and 
23andMe, while the y-axis shows the effect in the AOA vs. control meta-analysis of the same two 
studies. In panel A, variants for which the odds ratio in the AOA vs. control analysis was <1.005 are 
highlighted in red, with their genomic context also highlughted. Similarly, in panel B, variants in 
red had an odds ratio <1.005 in the COA vs. controls analysis. To help interpret the correlation in 
odds ratios between the two disease subtypes, regression lines with increasing beta coefficients 
(“b”, from 0.1 to 1) are shown in blue. 
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TABLES 
 
Table 1. Liability scale SNP-based heritability (diagonal) of, and genetic correlation (lower 
diagonal) between, childhood-onset asthma (COA) and adult-onset asthma (AOA) in the UK 
Biobank study. 
 COA (onset: 0-19) yAOA (onset: 20-39) oAOA (onset: 40-60) AOA (onset: 20-60) 
13,962 vs 433,306  11,709 vs 435,559  14,873 vs 432,395  26,582 vs 420,686  
COA  0.256 (0.007)  - - - 
yAOA  0.831 (0.032)  0.098 (0.006)  - - 
oAOA  0.469 (0.031)  0.856 (0.050)  0.078 (0.005)  - 
AOA  0.667 (0.023)  - - 0.106 (0.004)  
Standard error of the heritability estimate is shown in brackets. 
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Table 2.  Independent SNP associations with risk of childhood-onset asthma (COA) discovered in the UK Biobank study (13,962 cases vs. 300,671 1 
controls) and validated in the 23andMe study (31,759 cases vs. 214,890 controls). 2 
Chr Bp 
Sentinel 
SNP 
Context A1  
Discovery (UK Biobank) 
 
Replication (23andMe) 
 
Meta-analysis 
OR SE P-value 
A1 
freq 
OR SE P-value OR SE P-value 
Sentinel SNPs that represent novel associations for allergic disease 
1 9356676 rs67551275 [SPSB1] T  1.071 0.012 1.3E-08 0.53  1.067 0.010 5.9E-11  1.069 0.008 3.8E-18 
1 172715702 rs78037977 FASLG-[]--TNFSF18 A  1.116 0.018 1.4E-09 0.88  1.066 0.015 1.6E-05  1.086 0.011 6.2E-13 
1 213056427 rs12750027 [FLVCR1] A  1.150 0.024 3.9E-09 0.07  1.075 0.022 1.4E-03  1.109 0.016 2.6E-10 
2 224664050 rs6755248 [AP1S3] G  1.070 0.012 1.6E-08 0.41  1.046 0.009 1.3E-06  1.055 0.007 3.2E-13 
2 228670437 rs10187276 SLC19A3-[]-CCL20 T  1.116 0.014 7.0E-16 0.25  1.059 0.011 6.2E-08  1.079 0.009 1.5E-19 
3 127912846 rs11412402 [EEFSEC] D  1.073 0.012 3.2E-09 0.47  1.047 0.009 4.9E-07  1.057 0.007 3.9E-14 
3 176852038 rs7626218 [TBL1XR1] A  1.083 0.012 3.1E-11 0.60  1.031 0.009 1.5E-03  1.051 0.007 3.6E-11 
6 409119 rs9391997 [IRF4] G  1.077 0.012 3.1E-10 0.53  1.038 0.009 5.9E-05  1.052 0.007 3.8E-12 
7 22780322 rs6954667 IL6-[]-TOMM7 A  1.074 0.013 2.6E-08 0.31  1.028 0.010 6.0E-03  1.045 0.008 3.0E-08 
8 120063542 rs2450083 TNFRSF11B-[]-COLEC10 C  1.070 0.012 1.1E-08 0.50  1.037 0.009 1.2E-04  1.049 0.007 7.8E-11 
9 23585839 rs274943 DMRTA1---[]--ELAVL2 T  1.080 0.012 9.1E-11 0.52  1.051 0.009 6.8E-08  1.062 0.007 2.6E-16 
10 6093139 rs12722502 [IL2RA] C  1.326 0.044 2.0E-10 0.98  1.235 0.053 4.3E-05  1.288 0.034 6.8E-14 
10 6621773 rs943451 [PRKCQ] T  1.105 0.013 7.5E-15 0.31  1.041 0.010 4.7E-05  1.063 0.008 3.5E-15 
10 94384514 rs113092121 [KIF11] I  1.092 0.012 1.8E-13 0.56  1.058 0.009 1.8E-09  1.070 0.007 2.5E-20 
11 10664033 rs2052690 [MRVI1] T  1.077 0.013 1.5E-08 0.29  1.043 0.010 3.2E-05  1.056 0.008 1.1E-11 
11 36365253 rs10836538 [PRR5L] G  1.083 0.012 1.2E-10 0.65  1.040 0.010 5.4E-05  1.057 0.007 2.7E-13 
12 55368291 rs62623446 [TESPA1] T  1.138 0.023 1.7E-08 0.07  1.103 0.021 6.2E-06  1.119 0.016 8.0E-13 
13 99974492 rs1887704 [UBAC2] G  1.102 0.013 1.4E-14 0.68  1.059 0.010 4.8E-09  1.075 0.008 4.7E-20 
16 27349168 rs3785356 [IL4R] T  1.116 0.013 2.7E-17 0.29  1.073 0.010 2.5E-12  1.089 0.008 8.5E-27 
16 50745926 rs2066844 [NOD2] T  1.172 0.028 1.5E-08 0.05  1.086 0.022 2.5E-04  1.119 0.017 1.3E-10 
18 48647640 rs1893380 SMAD4-[]-MEX3C C  1.083 0.012 5.2E-11 0.38  1.039 0.009 5.7E-05  1.055 0.007 3.6E-13 
18 51816408 rs12965763 [POLI] A  1.100 0.014 2.3E-11 0.22  1.034 0.011 2.3E-03  1.059 0.009 4.3E-11 
19 1152656 rs892225 [SBNO2] G  1.080 0.012 3.4E-10 0.38  1.040 0.010 9.7E-05  1.057 0.008 1.1E-12 
23 13023741 rs850637 TMSB4X-[]-FAM9C G  1.064 0.010 2.2E-10 0.56  1.036 0.008 3.3E-06  1.046 0.006 8.3E-14 
23 49139787 rs5953283 [PPP1R3F] A  1.064 0.010 3.1E-10 0.40  1.024 0.008 2.2E-03  1.038 0.006 5.6E-10 
Sentinel SNPs in LD (r2>0.05) with variants previously reported to associate with allergic disease 
1 151801680 rs4845604 [RORC] G  1.140 0.017 9.5E-15 0.86  1.062 0.014 9.2E-06  1.092 0.011 1.5E-16 
1 152179152 rs12123821 RPTN-[]-HRNR T  1.523 0.028 4.0E-51 0.05  1.163 0.025 1.1E-09  1.307 0.018 7.6E-48 
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1 161185058 rs2070901 NDUFS2-[]-FCER1G T  1.093 0.013 2.4E-11 0.27  1.105 0.010 4.2E-22  1.100 0.008 2.8E-32 
1 167436270 rs1617333 [CD247] A  1.098 0.012 9.9E-15 0.60  1.061 0.009 4.3E-10  1.075 0.007 2.5E-22 
1 173131493 rs10158467 TNFSF18--[]-TNFSF4 G  1.116 0.013 6.3E-17 0.28  1.079 0.010 5.0E-14  1.093 0.008 8.3E-29 
1 203093201 rs12023876 MYOG-[]-ADORA1 G  1.080 0.012 7.8E-10 0.67  1.071 0.010 4.3E-12  1.074 0.008 4.9E-21 
2 8459404 rs3856439 [LINC00299] C  1.113 0.012 6.0E-18 0.66  1.070 0.010 7.0E-12  1.087 0.008 6.2E-28 
2 102798245 rs74180212 IL1R1-[]-IL1RL2 G  1.123 0.012 1.1E-20 0.44  1.087 0.010 1.6E-17  1.101 0.008 5.3E-37 
2 102882352 rs78545931 IL1RL2-[]-IL18R1 A  1.408 0.033 4.2E-25 0.98  1.391 0.027 5.9E-37  1.398 0.021 8.8E-59 
2 102936159 rs72823641 [IL18R1] T  1.341 0.017 6.9E-68 0.86  1.281 0.014 5.4E-75  1.305 0.011 2E-136 
2 102966906 rs1861245 [IL1RL1] C  1.194 0.013 9.3E-45 0.66  1.124 0.010 3.9E-32  1.150 0.008 2.3E-69 
2 112268732 rs143326447 BCL2L11--[]--ANAPC1 C  1.108 0.018 1.8E-08 0.12  1.047 0.015 2.0E-03  1.071 0.011 1.8E-09 
2 242698640 rs34290285 [D2HGDH] G  1.198 0.013 3.3E-41 0.74  1.142 0.012 5.5E-29  1.168 0.009 4.2E-69 
3 33047662 rs35570272 [GLB1] T  1.106 0.012 7.8E-17 0.39  1.029 0.009 2.3E-03  1.057 0.007 4.1E-14 
3 121716171 rs1806656 [ILDR1] C  1.082 0.013 6.3E-10 0.68  1.036 0.010 6.4E-04  1.053 0.008 1.2E-10 
3 141150026 rs7625643 [ZBTB38] G  1.070 0.012 2.1E-08 0.44  1.029 0.009 2.7E-03  1.044 0.007 4.9E-09 
3 188128979 rs9860547 [LPP] A  1.135 0.012 1.9E-26 0.45  1.087 0.009 1.5E-19  1.105 0.007 3.6E-42 
3 188401138 rs55661102 [LPP] A  1.101 0.016 9.0E-10 0.83  1.093 0.013 2.4E-12  1.096 0.010 4.1E-20 
4 38798648 rs5743618 [TLR1] C  1.210 0.014 2.1E-43 0.76  1.141 0.011 1.7E-36  1.165 0.008 3.2E-74 
4 123353432 rs17454584 ADAD1-[]-IL2 G  1.126 0.014 1.5E-16 0.21  1.106 0.011 2.1E-20  1.114 0.009 5.9E-36 
5 14610309 rs16903574 [FAM105A] G  1.191 0.023 2.1E-14 0.07  1.122 0.017 7.9E-12  1.145 0.013 1.0E-23 
5 110158844 rs7734635 SLC25A46-[]--TSLP G  1.176 0.016 3.7E-23 0.15  1.084 0.012 1.8E-11  1.116 0.009 1.9E-30 
5 110401872 rs1837253 SLC25A46--[]-TSLP C  1.182 0.013 1.2E-35 0.74  1.189 0.011 1.6E-59  1.186 0.008 7.1E-94 
5 110470137 rs6594499 WDR36-[]-CAMK4 C  1.147 0.012 3.3E-31 0.51  1.126 0.009 5.4E-38  1.134 0.007 3.9E-66 
5 131799626 rs3749833 [C5orf56] C  1.109 0.013 1.3E-14 0.26  1.057 0.011 2.2E-07  1.077 0.008 1.2E-19 
5 131916940 rs2299012 [RAD50] C  1.191 0.015 1.9E-31 0.19  1.115 0.011 7.6E-23  1.141 0.009 1.0E-49 
5 132105698 rs113010607 [SEPT8] C  1.172 0.022 4.1E-13 0.07  1.101 0.017 6.1E-09  1.126 0.013 2.0E-19 
5 141533062 rs449454 [NDFIP1] G  1.084 0.012 3.0E-11 0.62  1.070 0.010 1.1E-12  1.076 0.007 2.0E-22 
6 31303324 rs114444221 [HLA-B] A  1.231 0.027 2.3E-14 0.97  1.095 0.017 1.2E-07  1.133 0.015 9.0E-18 
6 33033824 rs111789468 [HLA-DPA1] T  1.222 0.030 1.3E-11 0.03  1.069 0.013 4.1E-07  1.092 0.012 2.2E-13 
6 33099538 rs3116989 HLA-DPB2-[]-COL11A2 G  1.151 0.017 5.3E-16 0.87  1.060 0.014 3.2E-05  1.096 0.011 2.6E-17 
6 90976609 rs62408233 [BACH2] G  1.113 0.012 2.9E-18 0.64  1.096 0.010 3.3E-21  1.103 0.008 2.8E-38 
6 106667535 rs9372120 [ATG5] G  1.106 0.015 5.5E-12 0.21  1.078 0.011 4.2E-11  1.088 0.009 8.8E-21 
6 128293562 rs55743914 [PTPRK] T  1.105 0.014 4.8E-13 0.24  1.051 0.011 5.0E-06  1.071 0.009 1.5E-15 
6 138002175 rs6927172 OLIG3--[]--LOC100130476 C  1.090 0.014 1.4E-09 0.78  1.051 0.011 1.1E-05  1.067 0.009 3.3E-13 
7 20423923 rs149317277 [ITGB8] D  1.087 0.012 6.6E-12 0.61  1.050 0.009 3.0E-07  1.064 0.007 8.4E-17 
7 20544209 rs12531500 ITGB8-[]--ABCB5 A  1.103 0.012 1.8E-16 0.57  1.056 0.009 5.3E-09  1.073 0.007 6.7E-22 
7 28156606 rs4722758 [JAZF1] G  1.126 0.015 6.2E-16 0.20  1.090 0.011 6.1E-15  1.103 0.009 2.8E-28 
8 81294702 rs2221641 MIR5708--[]--ZBTB10 C  1.112 0.012 2.4E-18 0.38  1.074 0.009 2.2E-14  1.088 0.007 1.8E-30 
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8 128777719 rs13277355 POU5F1B--[]-MYC A  1.103 0.013 1.4E-13 0.27  1.072 0.010 7.1E-12  1.084 0.008 9.5E-24 
9 6081804 rs340934 RANBP6-[]--IL33 T  1.208 0.015 1.6E-36 0.81  1.142 0.012 8.7E-30  1.167 0.009 3.1E-62 
9 6213468 rs7848215 RANBP6--[]-IL33 T  1.255 0.014 4.1E-63 0.25  1.181 0.010 1.3E-59  1.206 0.008 5E-115 
10 8606014 rs17144046 GATA3--[]---SFTA1P G  1.102 0.013 7.0E-13 0.28  1.044 0.010 3.3E-05  1.066 0.008 2.9E-15 
10 9049253 rs12413578 GATA3---[]---SFTA1P C  1.204 0.019 1.7E-22 0.89  1.160 0.016 7.7E-21  1.178 0.012 9.1E-41 
10 9064716 rs1612986 GATA3---[]---SFTA1P C  1.168 0.015 4.5E-24 0.18  1.110 0.012 8.3E-19  1.131 0.009 8.3E-41 
10 64391375 rs10995245 [ZNF365] A  1.073 0.012 1.3E-08 0.35  1.033 0.010 9.2E-04  1.048 0.007 3.6E-10 
11 65551957 rs479844 AP5B1-[]-OVOL1 G  1.116 0.012 1.4E-20 0.55  1.052 0.009 3.9E-08  1.075 0.007 3.2E-23 
11 76299431 rs55646091 WNT11--[]-LRRC32 A  1.513 0.028 3.9E-50 0.05  1.283 0.021 8.5E-30  1.364 0.017 5.9E-74 
11 76299649 rs11236797 WNT11--[]-LRRC32 A  1.214 0.012 2.4E-60 0.45  1.132 0.009 1.0E-41  1.162 0.007 1E-93 
11 118743286 rs12365699 DDX6-[]-CXCR5 G  1.141 0.016 6.1E-17 0.83  1.106 0.013 4.2E-16  1.119 0.010 4.3E-30 
11 128172836 rs140522418 KIRREL3-AS3---[]--ETS1 D  1.095 0.015 4.8E-09 0.82  1.039 0.012 1.9E-03  1.062 0.010 4.3E-10 
12 56389293 rs705700 [RAB5B] C  1.108 0.012 8.1E-18 0.42  1.060 0.009 4.3E-10  1.078 0.007 2.5E-24 
12 57509102 rs3122929 [STAT6] T  1.141 0.012 7.6E-28 0.40  1.067 0.009 5.7E-12  1.095 0.007 2.4E-34 
12 112059557 rs11065979 ATXN2-[]-BRAP C  1.085 0.012 6.5E-12 0.56  1.054 0.009 1.3E-08  1.066 0.007 4.8E-18 
12 121365431 rs188074962 SPPL3-[]-HNF1A-AS1 G  1.112 0.012 8.8E-18 0.35  1.048 0.010 1.9E-06  1.073 0.008 1.6E-20 
12 123635096 rs1716183 [PITPNM2] C  1.098 0.016 2.2E-09 0.83  1.049 0.013 1.2E-04  1.067 0.010 3.5E-11 
14 68754695 rs1885013 [RAD51B] G  1.098 0.013 1.0E-12 0.28  1.078 0.010 4.4E-14  1.085 0.008 2.9E-25 
14 103244070 rs71421264 [TRAF3] G  1.081 0.012 1.0E-10 0.59  1.032 0.009 7.2E-04  1.050 0.007 2.8E-11 
15 41787585 rs1655558 [ITPKA] G  1.087 0.012 2.8E-12 0.55  1.056 0.010 1.7E-08  1.068 0.007 2.2E-18 
15 61069988 rs11071559 [RORA] C  1.185 0.017 1.9E-22 0.87  1.121 0.014 2.5E-17  1.145 0.011 2.0E-37 
15 67441750 rs72743461 [SMAD3] A  1.196 0.014 1.7E-37 0.23  1.127 0.011 3.8E-29  1.152 0.009 6.4E-63 
15 67475764 rs34445740 [SMAD3] D  1.111 0.013 4.7E-16 0.70  1.055 0.010 1.8E-07  1.076 0.008 7.7E-20 
16 11219041 rs12935657 [CLEC16A] G  1.154 0.014 6.1E-26 0.75  1.122 0.011 1.3E-27  1.133 0.009 1.0E-49 
17 38061439 rs4795399 [GSDMB] T  1.303 0.012 3E-111 0.53  1.280 0.009 2E-155  1.289 0.007 1E-257 
17 38064971 rs117097909 [GSDMB] A  1.355 0.026 1.5E-31 0.05  1.247 0.022 3.7E-22  1.292 0.017 1.6E-51 
17 38755021 rs9893132 CCR7-[]-SMARCE1 G  1.095 0.012 1.4E-13 0.64  1.047 0.010 1.7E-06  1.065 0.007 3.0E-17 
17 38764524 rs112401631 CCR7-[]-SMARCE1 A  1.354 0.043 1.6E-12 0.02  1.265 0.044 1.9E-07  1.310 0.031 2.1E-18 
17 43457886 rs9895436 MAP3K14-[]-ARHGAP27 A  1.089 0.012 1.8E-12 0.40  1.058 0.009 1.4E-09  1.070 0.007 5.9E-20 
17 47448346 rs12952581 ZNF652-[]-PHB A  1.094 0.012 2.4E-13 0.36  1.069 0.010 3.2E-12  1.078 0.007 4.4E-24 
18 60009814 rs4574025 [TNFRSF11A] T  1.092 0.012 1.3E-13 0.53  1.036 0.010 2.2E-04  1.058 0.007 8.0E-14 
18 61442619 rs12964116 [SERPINB7] G  1.293 0.031 3.0E-16 0.04  1.143 0.041 1.1E-03  1.236 0.025 8.4E-18 
19 8785744 rs2918302 ADAMTS10--[]-ACTL9 A  1.107 0.016 5.8E-10 0.15  1.037 0.013 3.5E-03  1.064 0.010 4.8E-10 
19 33726578 rs117710327 SLC7A10-[]-CEBPA C  1.205 0.024 4.7E-15 0.94  1.189 0.021 1.2E-16  1.196 0.016 2.8E-29 
 3 
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Table 3. Independent SNP associations with risk of adult-onset asthma (AOA) discovered in the UK Biobank study (26,582 cases vs. 300,671 controls) 5 
and validated in the 23andMe study (16,297 cases vs. 217,711 controls). 6 
Chr Bp 
Sentinel 
SNP 
Context A1  
Discovery (UK Biobank) 
 
Replication (23andMe) 
 
Meta-analysis 
OR SE P-value 
A1 
freq 
OR SE P-value OR SE P-value 
Sentinel SNPs that represent novel associations for allergic disease 
1 198640488 rs17668708 [PTPRC] C  1.096 0.014 2.4E-11 0.90  1.069 0.020 6.9E-04  1.087 0.011 3.0E-13 
2 146145018 rs2381712 TEX41--[]---PABPC1P2 G  1.056 0.008 9.5E-11 0.52  1.057 0.012 4.9E-06  1.056 0.007 2.5E-16 
10 6093139 rs12722502 [IL2RA] C  1.237 0.032 1.9E-11 0.98  1.156 0.067 2.8E-02  1.222 0.029 4.3E-12 
13 40319954 rs28635831 [COG6] A  1.051 0.009 1.7E-08 0.65  1.030 0.013 1.9E-02  1.044 0.007 4.3E-09 
13 100070457 rs4771332 MIR548AN-[]-TM9SF2 C  1.061 0.009 9.8E-11 0.69  1.035 0.013 9.5E-03  1.053 0.007 5.5E-12 
16 27369502 rs3024655 [IL4R] G  1.133 0.018 1.1E-12 0.94  1.051 0.025 4.9E-02  1.105 0.015 1.1E-11 
Sentinel SNPs in LD (r2>0.05) with variants previously reported to associate with allergic disease 
1 167420299 rs2056625 [CD247] G  1.060 0.009 5.6E-12 0.59  1.027 0.012 2.9E-02  1.048 0.007 7.6E-11 
2 102892339 rs60227565 IL1RL2-[]-IL18R1 G  1.146 0.012 1.8E-28 0.87  1.082 0.018 7.7E-06  1.125 0.010 1.4E-32 
2 102926362 rs12470864 IL1RL2-[]-IL18R1 A  1.104 0.009 2.3E-30 0.38  1.061 0.012 1.5E-06  1.089 0.007 1.1E-31 
2 242698640 rs34290285 [D2HGDH] G  1.100 0.010 2.9E-23 0.74  1.091 0.016 1.8E-08  1.097 0.008 2.2E-28 
3 33083985 rs4491851 [GLB1] A  1.056 0.008 1.0E-10 0.53  1.035 0.012 4.0E-03  1.050 0.007 3.7E-13 
4 123359569 rs62322662 ADAD1-[]-IL2 G  1.096 0.016 8.1E-09 0.08  1.059 0.023 1.2E-02  1.084 0.013 7.9E-10 
5 35881376 rs11742240 IL7R-[]-CAPSL G  1.063 0.009 6.1E-11 0.72  1.045 0.014 1.1E-03  1.058 0.007 9.1E-14 
5 110161473 rs540485182 SLC25A46-[]--TSLP I  1.090 0.012 1.7E-13 0.15  1.058 0.016 4.2E-04  1.078 0.010 3.8E-15 
5 110401872 rs1837253 SLC25A46--[]-TSLP C  1.084 0.010 2.9E-17 0.74  1.055 0.014 1.1E-04  1.074 0.008 1.4E-18 
5 110408002 rs1898671 [TSLP] T  1.082 0.009 5.5E-19 0.35  1.060 0.013 4.9E-06  1.074 0.007 1.4E-22 
5 131787137 rs6866614 [IRF1] G  1.075 0.009 2.0E-17 0.57  1.074 0.012 6.9E-09  1.075 0.007 4.4E-23 
5 141518940 rs10699671 [NDFIP1] I  1.051 0.009 9.9E-09 0.61  1.055 0.012 1.6E-05  1.052 0.007 2.4E-12 
6 90985198 rs58521088 [BACH2] A  1.074 0.009 5.1E-16 0.64  1.026 0.013 4.6E-02  1.058 0.007 2.5E-14 
8 81302012 rs35204956 MIR5708--[]-ZBTB10 D  1.063 0.009 2.2E-12 0.39  1.057 0.012 6.9E-06  1.061 0.007 4.0E-16 
9 6047765 rs62557312 RANBP6-[]--IL33 C  1.104 0.011 2.0E-19 0.82  1.049 0.016 2.1E-03  1.085 0.009 8.0E-20 
9 6209697 rs992969 RANBP6--[]-IL33 A  1.115 0.010 2.4E-29 0.25  1.059 0.014 2.8E-05  1.095 0.008 2.0E-29 
10 8777640 rs10795672 GATA3---[]---SFTA1P A  1.061 0.009 5.4E-12 0.47  1.040 0.013 2.5E-03  1.054 0.007 1.0E-12 
10 9054340 rs1775554 GATA3---[]---SFTA1P A  1.109 0.008 3.0E-34 0.57  1.085 0.012 4.2E-11  1.102 0.007 3.1E-47 
11 76293726 rs7936312 WNT11--[]-LRRC32 T  1.089 0.008 6.1E-24 0.47  1.062 0.012 5.8E-07  1.081 0.007 2.5E-31 
12 48186563 rs2544026 [HDAC7] T  1.060 0.010 1.7E-09 0.75  1.066 0.014 6.2E-06  1.062 0.008 2.0E-13 
12 56449435 rs7302200 RPS26-[]-ERBB3 A  1.071 0.009 1.8E-14 0.34  1.036 0.013 5.3E-03  1.059 0.007 4.4E-15 
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12 57489709 rs1059513 [STAT6] T  1.119 0.013 5.3E-17 0.89  1.072 0.020 3.7E-04  1.105 0.011 4.7E-20 
15 61049569 rs7183955 [RORA] A  1.070 0.011 4.3E-10 0.81  1.049 0.015 1.6E-03  1.063 0.009 8.3E-12 
15 67441750 rs72743461 [SMAD3] A  1.097 0.010 1.7E-20 0.23  1.067 0.014 3.8E-06  1.087 0.008 1.4E-24 
16 11213021 rs35441874 [CLEC16A] T  1.081 0.010 1.1E-15 0.75  1.067 0.014 2.5E-06  1.076 0.008 1.2E-19 
17 47465743 rs10667251 ZNF652-[]-PHB D  1.049 0.009 2.2E-08 0.58  1.033 0.012 9.0E-03  1.043 0.007 5.4E-09 
19 33726578 rs117710327 SLC7A10-[]-CEBPA C  1.152 0.017 9.3E-17 0.94  1.089 0.027 1.5E-03  1.134 0.014 2.8E-18 
21 36464631 rs11088309 [RUNX1] G  1.088 0.012 2.4E-12 0.14  1.035 0.017 4.7E-02  1.070 0.010 5.2E-12 
 7 
8 
 42 
 
Table 4. Genes with a sentinel eQTL and/or non-synonymous SNP in LD (r2≥0.8) with sentinel asthma risk variants identified in the GWAS of COA or 9 
AOA. 10 
Chr Bp 
Sentinel 
SNP 
Novel 
association 
Context 
LD between sentinel eQTL/non-synonymous SNP and sentinel GWAS SNP* 
r2≥0.95 0.8 ≤ r2 < 0.95 
Sentinel SNPs identified in the GWAS of COA 
1 151801680 rs4845604 No [RORC] RORC,TUFT1 - 
1 161185058 rs2070901 No NDUFS2-[]-FCER1G F11R,FCER1G,TOMM40L,USF1 - 
1 167436270 rs1617333 No [CD247] CD247 - 
1 173131493 rs10158467 No TNFSF18--[]-TNFSF4 TNFSF4 - 
1 203093201 rs12023876 No MYOG-[]-ADORA1 
ADORA1,CHIT1,MYBPH,PPFIA4,RP11-
335O13.7 
- 
1 213056427 rs12750027 Yes [FLVCR1] - FLVCR1,FLVCR1-AS1 
2 102882352 rs78545931 No IL1RL2-[]-IL18R1 IL18RAP,IL1RL1 MFSD9 
2 102936159 rs72823641 No [IL18R1] MFSD9 - 
2 102966906 rs1861245 No [IL1RL1] - AC007278.3,IL18R1,IL1RL1 
2 228670437 rs10187276 Yes SLC19A3-[]-CCL20 CCL20 - 
2 242698640 rs34290285 No [D2HGDH] PDCD1 - 
3 141150026 rs7625643 No [ZBTB38] - ZBTB38 
3 188128979 rs9860547 No [LPP] BCL6 - 
4 38798648 rs5743618 No [TLR1] TLR1 - 
4 123353432 rs17454584 No ADAD1-[]-IL2 KIAA1109 - 
5 14610309 rs16903574 No [FAM105A] FAM105A - 
5 110470137 rs6594499 No WDR36-[]-CAMK4 - CTC-551A13.2,TSLP,WDR36 
5 131799626 rs3749833 No [C5orf56] C5orf56,SLC22A4 - 
5 131916940 rs2299012 No [RAD50] SLC22A5 - 
5 141533062 rs449454 No [NDFIP1] NDFIP1 - 
6 31303324 rs114444221 No [HLA-B] - HLA-C,NOTCH4 
6 33033824 rs111789468 No [HLA-DPA1] HLA-DPA1 HLA-DPB1,HLA-DQB1,TAPBP 
7 20423923 rs149317277 No [ITGB8] - ITGB8 
7 28156606 rs4722758 No [JAZF1] JAZF1 - 
10 6093139 rs12722502 Yes [IL2RA] IL2RA - 
10 6621773 rs943451 Yes [PRKCQ] PRKCQ - 
10 94384514 rs113092121 Yes [KIF11] - EIF2S2P3,HHEX,KIF11 
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11 10664033 rs2052690 Yes [MRVI1] - RNF141 
11 36365253 rs10836538 Yes [PRR5L] PRR5L - 
11 65551957 rs479844 No AP5B1-[]-OVOL1 OVOL1 EFEMP2,SNX32 
11 76299649 rs11236797 No WNT11--[]-LRRC32 LRRC32 - 
11 128172836 rs140522418 No KIRREL3-AS3---[]--ETS1 - ETS1 
12 55368291 rs62623446 Yes [TESPA1] TESPA1 - 
12 56389293 rs705700 No [RAB5B] RPS26,SUOX - 
12 112059557 rs11065979 No ATXN2-[]-BRAP TCTN1,TRAFD1 SH2B3 
12 121365431 rs188074962 No SPPL3-[]-HNF1A-AS1 SPPL3 - 
13 99974492 rs1887704 Yes [UBAC2] - GPR183,UBAC2 
14 103244070 rs71421264 No [TRAF3] TRAF3 - 
15 41787585 rs1655558 No [ITPKA] - D-JC17,ITPKA,RTF1,ZFYVE19 
15 61069988 rs11071559 No [RORA] - RP11-554D20.1 
15 67441750 rs72743461 No [SMAD3] AAGAB - 
15 67475764 rs34445740 No [SMAD3] SMAD3 - 
16 11219041 rs12935657 No [CLEC16A] - SOCS1 
16 27349168 rs3785356 Yes [IL4R] NSMCE1 IL4R 
16 50745926 rs2066844 Yes [NOD2] NOD2 - 
17 38061439 rs4795399 No [GSDMB] GSDMB,ORMDL3 GSDMA,IKZF3,RP11-94L15.2,ZPBP2 
17 38755021 rs9893132 No CCR7-[]-SMARCE1 SMARCE1 - 
17 43457886 rs9895436 No MAP3K14-[]-ARHGAP27 
CRHR1,CRHR1-
IT1,DND1P1,LRRC37A4P,RP11-105N13.4 
- 
17 47448346 rs12952581 No ZNF652-[]-PHB GNGT2 - 
18 48647640 rs1893380 Yes SMAD4-[]-MEX3C RP11-729L2.2,SMAD4 - 
18 60009814 rs4574025 No [TNFRSF11A] PIGN - 
18 61442619 rs12964116 No [SERPINB7] SERPINB7 - 
19 1152656 rs892225 Yes [SBNO2] GPX4 - 
Sentinel SNPs identified in the GWAS of AOA 
1 167420299 rs2056625 No [CD247] CD247 - 
2 102892339 rs60227565 No IL1RL2-[]-IL18R1 - IL18RAP,IL1RL1,MFSD9 
2 102926362 rs12470864 No IL1RL2-[]-IL18R1 IL18R1 IL18RAP 
2 242698640 rs34290285 No [D2HGDH] PDCD1 - 
4 123353432 rs17454584 No ADAD1-[]-IL2 KIAA1109 - 
5 35881376 rs11742240 No IL7R-[]-CAPSL IL7R - 
5 131787137 rs6866614 No [IRF1] AC116366.5,P4HA2,SLC22A5 IRF1,SLC22A4 
5 141518940 rs10699671 No [NDFIP1] NDFIP1 - 
10 6093139 rs12722502 Yes [IL2RA] IL2RA - 
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11 76293726 rs7936312 No WNT11--[]-LRRC32 - LRRC32 
12 48186563 rs2544026 No [HDAC7] - HDAC7,RPAP3 
12 56449435 rs7302200 No RPS26-[]-ERBB3 ERBB3,GDF11,IKZF4,RAB5B,RPS26,SUOX CDK2 
12 57489709 rs1059513 No [STAT6] METTL21B,NAB2,STAT6 - 
13 40319954 rs28635831 Yes [COG6] - COG6 
13 100070457 rs4771332 Yes MIR548AN-[]-TM9SF2 CCR12P - 
15 67441750 rs72743461 No [SMAD3] AAGAB - 
* The font pattern used for gene names is as follows. Italic: genes implicated by an eQTL but not by a non-synonymous variant. Italic and bold: genes 11 
implicated by a non-synonymous variant but not an eQTL. Italic and underlined: genes implicated by both an eQTL and a non-synonymous variant. 12 
13 
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